You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
The share prices of 20 companies in the 360Dx Index rose last month, with Exact Sciences, Natera, Invitae, and NeoGenomics the biggest gainers.
The company said test volume rose 87 percent to 186,000 during the quarter.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Armune, a University of Michigan spinout, owns licensing rights to protein biomarkers from the university for lung, breast, and prostate cancer.
Underwriter Merrill Lynch exercised in full the option to purchase up to an additional $90M in senior notes on top of a $600M notes offering announced last week.